Top Story
Real World DataWhile recent studies confirm semaglutide's efficacy in significant weight reduction among overweight and obese adults, limited real-world data has confirmed these effects. This retrospective study from Tzoulis et al. evaluated the effectiveness and safety of semaglutide in 40 non-diabetic adults that had a reported average weight [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
05/06/2024 04:46 PM ET
Calliditas Therapeutics AB CALT date announcement
On December 31, 2024, Calliditas Therapeutics AB will announce top-line results for their recent Phase 2 trial for Setanaxib with pembrolizumab. Our model suggests the drug has a 33.7% chance of progressing.
Calliditas Therapeutics AB [...]
Read More
05/06/2024 04:46 PM ET
NRX Pharmaceuticals LTRN results announcement
Lantern Pharma provided an update to their trial for XCE853. Our analysts summarized the update as follows:
"Development announced May 6, 2024. Trial planned."
Investors seemed to like what they heard. Lantern Pharma rocketed [...]
Read More
05/06/2024 04:46 PM ET
Alpha Tau Medical Ltd. DRTS date announcement
Alpha Tau Medical Ltd., makers of Alpha DaRT, will be announcing their top-line results for the drug's recent Phase 1a trial on December 31, 2024. Our predictive system gives the drug a 60.9% chance [...]
Read More
Search HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
